• 1
    Porcellati F, Rossetti P, Busciantella NR, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes. Diabetes Care 2007; 30: 24472452.
  • 2
    Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443445.
  • 3
    Fischer JS, Edelman SV, Schwartz SL. United States patient preference and usability for the new disposable insulin device Solostar versus other disposable pens. J Diabetes Sci Technol 2008; 2: 11571160.
  • 4
    Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006; 145: 125134.
  • 5
    Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193203.
  • 6
    Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetologia 2006; 49: 17111721.
  • 7
    Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 17161730.
  • 8
    Hermansen K, Mortensen LS, Hermansen ML. Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. Vasc Health Risk Manag 2008; 4: 561574.
  • 9
    Khunti K, Srinivasan BT, Shutler S, et al. Effect of insulin glargine on glycemic control and weight in obese and non-obese people with type 2 diabetes: data from the AT.LANTUS trial. Diabetes Obes Metab 2010; 12: 683688.
  • 10
    Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330336.
  • 11
    The Diabetes Control Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 12891298.
  • 12
    Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103117.
  • 13
    American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care 2008; 31(Suppl. 1): S12S54.
  • 14
    The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212228.
  • 15
    Riddle MC, Rosenstock J, Gerich J. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients (The Treat-to-Target Trial). Diabetes Care 2003; 36: 30803086.
  • 16
    Buse JB, Wolffenbuttel BHR, Herman WH, et al. Durability of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week, Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009; 32: 10071013.
  • 17
    Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: LANMET study. Diabetologia 2006; 49: 442451.
  • 18
    Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 10731084.
  • 19
    Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia 2008; 51: 408416.
  • 20
    Goto H, Hirose T, Shimizu T, et al. Effectiveness of combination therapy with a sulfonylurea and once-daily insulin glargine in Japanese type 2 diabetic patients: evaluation of long-term (18 months) results of the combination therapy. J Jpn Diabetes Soc 2007; 50: 591597.
  • 21
    Kawamori R, Iwamoto Y, Kadowaki T, et al. Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of type 2 diabetic patients. Rinsho Iyaku 2003; 19: 445464 (Japanese).
  • 22
    Sone H, Kawai K, Takagi H, et al. Outcome of one-year of specialist care of patients with type 2 diabetes: a multi-center prospective survey (JDDM 2). Intern Med 2006; 45: 589597.
  • 23
    UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years therapy of type 2 diabetes. A progressive disease. Diabetes 1995; 44: 12491258.
  • 24
    Lebovitz HE. Insulin secretogogues: old and new. Diabetes Rev 1999; 7: 139153.
  • 25
    Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Diabetes Care 2005; 28: 26732679.
  • 26
    Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl. 3): S18S24.
  • 27
    Valitutto M. Common crossroad in diabetes management. Osteopath Med Prim Care 2008; 2: 4.